Table 1

Publications correlating increased TMB with response to PD-1/PD-L1 therapy

IndicationTherapyTMB cut-offPanelVariant types includedRef.
MelanomaIpilimumab>2.5/ Mb*WESNon-synonymous 31
NSCLCPembrolizumab>4.5/ Mb*WESNon-synonymous 32
NSCLCNivolumab+Ipilimumab>4.0/ Mb*WESNon-synonymous 33
NSCLCNivolumab+Ipilimumab>10/ MbFMAll coding 34–36
NSCLCAnti-PD-1 or -PD-L1DescriptiveMSKNon-synonymous 37
MelanomaIpilimumabDescriptiveWESNon-synonymous 38
UrothelialAtezolizumabDescriptiveFMAll coding 39
NSCLCNivolumab>6.2/ Mb*WESNon-synonymous 40
MultipleAnti- CTLA4/PD-1/PD-L1>20/ MbFMAll coding 13
MultipleAnti- CTLA4/PD-1/PD-L1Tumor dependentMSKNon-synonymous 41
  • *39.4 Mb/exome.

  • FM, foundation medicine foundation one CDx assay; MSK, memorial sloan kettering IMPACT assay; NSCLC, non-small-cell lung cancer; TMB, tumor mutation burden; WES, whole-exome sequencing.